Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
trial tags : Research save search
Kiromic BioPharma Reports Consistent Favorable Safety, Tolerability, and Efficacy in Deltacel-01 Clinical Trial First Three Patients
Published: 2024-04-24 (Crawled : 14:00) - biospace.com/
KRBP | $2.64 -90.21% 360
|
Health Technology
|
| O: 0.0%
H: 11.74%
C: 2.65%
first favorable biopharma trial
Calliditas Therapeutics Presents Additional Data Analyses from the Phase 3 NeflgArd trial of Nefecon in Primary IgA Nephropathy at the ISN World Congress of Nephrology 2024
Published: 2024-04-18 (Crawled : 12:00) - biospace.com/
CALT | $18.5 1.65% 1.62% 1.5K
|
Health Technology
|
| O: -0.87%
H: 3.58%
C: -2.86%
nephropathy congress world nefecon trial therapeutics
Ventus Therapeutics Announces Results from Phase 1 Clinical Trial of VENT-02, a Novel, Orally Administered, Brain-Penetrant NLRP3 Inhibitor
Published: 2024-04-17 (Crawled : 14:00) - biospace.com/
NVO | News | $126.16 -1.93% -0.23% 3.1M
|
Health Technology
|
| O: 1.22%
H: 0.21%
C: -0.34%
vent-02 trial therapeutics results
Longeveron’s CLEAR MIND Randomized Phase 2a Clinical Trial Evaluating Lomecel-B™ in Mild Alzheimer’s Disease Accepted for Featured Research Session Oral Presentation at the 2024 Alzheimer’s Association International Conference (AAIC)
Published: 2024-04-15 (Crawled : 13:00) - globenewswire.com
LGVN 4 d | $1.73 -4.95% -5.2% 300K
|
|
| O: 41.42%
H: 42.68%
C: 22.59%
conference disease association alzheimer’s presentation international research for trial
Kiora Pharmaceuticals Receives Grant from Choroideremia Research Foundation to Fund Novel Clinical Trial Endpoints for Inherited Retinal Diseases; Approval Granted to Initiate Clinical Validation Study
Published: 2024-04-11 (Crawled : 17:00) - biospace.com/
KPRX | $0.504 -13.03% -14.98% 290K
|
Manufacturing
|
| O: 3.23%
H: 0.16%
C: -1.79%
granted approval pharmaceuticals research for grant trial foundation study
Entera Bio Announces Publication of Oral PTH(1-34) Peptide Tablets (EB613) Phase 2 Trial Data in the Journal of Bone and Mineral Research
Published: 2024-04-08 (Crawled : 12:30) - globenewswire.com
ENTX | $2.07 -6.76% -7.25% 160K
|
Health Technology
|
| O: 2.3%
H: 1.25%
C: -2.5%
eb613 publication research bone trial
Interim Results from the ARTACUS Clinical Trial of RP1 Monotherapy in Solid Organ and Hematopoietic Cell Transplant Recipients with Skin Cancers Presented During Oral Presentation at the American Association of Cancer Research (AACR) 2024 Annual Meeting
Published: 2024-04-07 (Crawled : 00:00) - globenewswire.com
REPL | $6.32 -1.56% -1.58% 630K
|
Health Technology
|
| O: 3.27%
H: 0.13%
C: -4.17%
association presentation cancer cell research meeting skin trial results
Natera Announces Positive Surveillance Analysis from the Randomized Phase III IMvigor011 Trial in Muscle-Invasive Bladder Cancer
Published: 2024-04-05 (Crawled : 12:30) - biospace.com/
NTRA | News M | $91.47 0.47% 0.47% 810K
|
Health Services
|
| O: 2.12%
H: 4.35%
C: 2.25%
bladder positive cancer trial
Halberd's Patented Drug, LDN+, the Subject of a Limited Clinical Trial Under an Innovative Four-Company Cooperative Research and Development (CRADA) Contract
Published: 2024-04-04 (Crawled : 19:00) - biospace.com/
HALB | $0.0082 7.14% 540K
|
n/a
|
| O: 3.49%
H: 7.23%
C: 1.2%
contract research trial
Tempest Announces Publication of Positive Data from Phase 1 Trial of TPST-1120 in Patients with Advanced Solid Tumors in Journal of Cancer Research Communications
Published: 2024-04-04 (Crawled : 12:00) - globenewswire.com
TPST | $3.43 0.29% 0.29% 650K
|
Manufacturing
|
| O: 8.39%
H: 2.71%
C: -12.96%
tpst-1120 tumors positive cancer publication research communications trial advanced
Moleculin Announces Positive Interim Data in Annamycin MB-106 Phase 1B/2 AML Trial
Published: 2024-03-25 (Crawled : 14:00) - biospace.com/
MBRX | $4.6 3.37% 7.4K
|
Health Technology
|
| O: 5.18%
H: 0.0%
C: -12.5%
mb-106 positive aml trial
Lantern Pharma Announces Initial Patients Dosed in First-In-Human Clinical Trial for AI-Guided Drug-Candidate, LP-284
Published: 2024-03-15 (Crawled : 13:30) - biospace.com/
LTRN | News | $5.44 -5.72% -6.07% 96K
|
Health Technology
|
| O: 2.04%
H: 18.0%
C: 16.0%
lp-284 pharma trial
Phio Pharmaceuticals Announces Addition of Clinical Trial Sites at Banner MD Anderson Cancer Center, The George Washington University, and Integrity Research
Published: 2024-03-13 (Crawled : 18:00) - globenewswire.com
PHIO | News | $0.672 -4.0% -4.17% 91K
|
Health Technology
|
| O: 1.96%
H: 0.0%
C: -9.48%
cancer pharmaceuticals research trial
Data from Atossa’s Phase 2 EVANGELINE Clinical Trial to be Presented at American Association for Cancer Research (AACR) Annual Meeting
Published: 2024-03-06 (Crawled : 14:00) - globenewswire.com
ATOS | $1.505 1.01% 1.0% 1.9M
|
Health Technology
|
| O: 1.96%
H: 15.38%
C: 10.58%
association cancer research meeting trial
Medicenna to Provide Clinical Update on the MDNA11 ABILITY-1 Trial at the Upcoming American Association for Cancer Research Annual Meeting
Published: 2024-03-06 (Crawled : 12:00) - globenewswire.com
MDNAF | $1.14 -17.54% 58K
|
n/a
|
| O: 3.0%
H: 6.12%
C: 0.36%
mdna11 association update cancer research meeting trial
Kiromic BioPharma Adds Virginia Oncology Associates, PC as the Second Clinical Trial Site in the Ongoing Phase 1 Deltacel-01 Trial
Published: 2024-03-01 (Crawled : 13:30) - biospace.com/
KRBP | $2.64 -90.21% 360
|
Health Technology
|
| O: -4.03%
H: 0.0%
C: -5.6%
biopharma ongoing trial
Medidata and Thermo Fisher Scientific’s PPD Clinical Research Business Collaborate to Accelerate Clinical Trials Innovation
Published: 2024-02-28 (Crawled : 13:30) - biospace.com/
TMO | News | $577.39 0.49% 0.0% 2M
|
Health Technology
|
| O: -0.17%
H: 1.38%
C: 1.21%
business innovation trials research
AceLink Therapeutics Announces Publication of Phase 1 Clinical Trial Data Evaluating AL01211 in Healthy Volunteers
Published: 2024-02-26 (Crawled : 15:30) - biospace.com/
BW | News | $1.06 15.57% 0.0% 2M
|
Electronic Technology
|
| O: 0.0%
H: 3.7%
C: 0.93%
al0121 publication trial therapeutics
Pulmonx Announces Treatment of the First Patient with the AeriSeal® System in CONVERT II Pivotal Trial
Published: 2024-02-26 (Crawled : 15:30) - biospace.com/
LUNG | $7.525 0.33% 0.33% 200K
|
Health Technology
|
| O: -0.65%
H: 3.35%
C: -3.26%
aeriseal first treatment system trial
ImmunityBio Announces Full Accrual of First Two Phases of Cancer Vaccine Trial in Participants with Lynch Syndrome and Initiation of Randomized Controlled Phase of the Trial
Published: 2024-02-21 (Crawled : 15:00) - biospace.com/
IBRX | $4.815 -12.3% -14.02% 7.9M
|
Manufacturing
|
| O: 1.27%
H: 0.31%
C: -2.3%
first vaccine cancer trial
Gainers vs Losers
| 62% | 38% |
Top 10 Gainers
CSSE 4 | $0.4323 183.85% 64.77% 220M
|
Consumer Services
BOF | $1.99 70.09% 41.21% 110M
|
ILAG | $0.51 6.03% 40.62% 1.7M
|
LICN | $0.941 68.04% 40.49% 15M
|
AMST | $3.31 65.5% 39.58% 70M
|
Technology Services
MTC | $3.615 61.38% 38.04% 9.3M
|
Technology Services
WIMI | $1.15 58.53% 36.92% 19M
|
Technology Services
AIH | $0.45 12.5% 30.92% 320K
|
Health Services
MULN | News | $3.78 38.46% 27.78% 13M
|
Information
RILY | $29.86 37.48% 27.26% 12M
|
Finance
Your saved searches
Save your searches and get alerts when important news are released.